JP2024538694A5 - - Google Patents
Info
- Publication number
- JP2024538694A5 JP2024538694A5 JP2024520826A JP2024520826A JP2024538694A5 JP 2024538694 A5 JP2024538694 A5 JP 2024538694A5 JP 2024520826 A JP2024520826 A JP 2024520826A JP 2024520826 A JP2024520826 A JP 2024520826A JP 2024538694 A5 JP2024538694 A5 JP 2024538694A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252394P | 2021-10-05 | 2021-10-05 | |
| US63/252,394 | 2021-10-05 | ||
| PCT/US2022/077501 WO2023060057A1 (en) | 2021-10-05 | 2022-10-04 | Cyclopentylpyrazole cdk2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024538694A JP2024538694A (ja) | 2024-10-23 |
| JP2024538694A5 true JP2024538694A5 (https=) | 2025-10-10 |
| JPWO2023060057A5 JPWO2023060057A5 (https=) | 2025-10-10 |
Family
ID=84245758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520826A Pending JP2024538694A (ja) | 2021-10-05 | 2022-10-04 | シクロペンチルピラゾールｃｄｋ２阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240425478A1 (https=) |
| EP (1) | EP4412995A1 (https=) |
| JP (1) | JP2024538694A (https=) |
| KR (1) | KR20240077491A (https=) |
| CN (1) | CN118019734A (https=) |
| AR (1) | AR127247A1 (https=) |
| AU (1) | AU2022360968A1 (https=) |
| CA (1) | CA3229067A1 (https=) |
| TW (1) | TW202330501A (https=) |
| WO (1) | WO2023060057A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN119072471A (zh) * | 2022-04-28 | 2024-12-03 | 正大天晴药业集团股份有限公司 | 一种吡唑取代环戊酯衍生物及其用途 |
| CN120239698A (zh) * | 2022-11-17 | 2025-07-01 | 山东绿叶制药有限公司 | Cdk2抑制剂及其制备方法和应用 |
| WO2025136671A1 (en) * | 2023-12-20 | 2025-06-26 | Ensem Therapeutics, Inc. | Anilino-pyrazole derivatives, compositions and methods thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113330000B (zh) * | 2019-01-31 | 2024-12-24 | 辉瑞公司 | 具有对cdk2的抑制活性的3-羰基氨基-5-环戊基-1fi-吡咯化合物 |
| CN110536068B (zh) | 2019-09-29 | 2021-09-28 | Oppo广东移动通信有限公司 | 对焦方法和装置、电子设备、计算机可读存储介质 |
| TW202246255A (zh) * | 2021-02-12 | 2022-12-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
-
2022
- 2022-10-04 AU AU2022360968A patent/AU2022360968A1/en active Pending
- 2022-10-04 TW TW111137712A patent/TW202330501A/zh unknown
- 2022-10-04 CA CA3229067A patent/CA3229067A1/en active Pending
- 2022-10-04 US US18/698,664 patent/US20240425478A1/en active Pending
- 2022-10-04 WO PCT/US2022/077501 patent/WO2023060057A1/en not_active Ceased
- 2022-10-04 KR KR1020247011084A patent/KR20240077491A/ko active Pending
- 2022-10-04 AR ARP220102682A patent/AR127247A1/es unknown
- 2022-10-04 JP JP2024520826A patent/JP2024538694A/ja active Pending
- 2022-10-04 CN CN202280065852.1A patent/CN118019734A/zh active Pending
- 2022-10-04 EP EP22800510.4A patent/EP4412995A1/en active Pending